您的购物车当前为空
SHR-2042 是一种GLP-1受体的选择性激动剂。通过激活GLP-1受体,SHR-2042 增强胰岛素的分泌并抑制胰高血糖素的分泌,从而改善血糖控制。当与 sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) 结合时,通过形成胶束能够促进单体化,提高口服吸收效率。
SHR-2042 是一种GLP-1受体的选择性激动剂。通过激活GLP-1受体,SHR-2042 增强胰岛素的分泌并抑制胰高血糖素的分泌,从而改善血糖控制。当与 sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) 结合时,通过形成胶束能够促进单体化,提高口服吸收效率。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 待询 | |
| 50 mg | 待询 | 待询 |
SHR-2042 相关产品
| 产品描述 | SHR-2042 is a selective agonist of the GLP-1 receptor. By activating the GLP-1 receptor, it enhances insulin secretion and suppresses glucagon secretion, thereby improving blood sugar regulation. When combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), it forms micelles that promote monomerization, increasing oral absorption efficiency. |
| 分子式 | C205H314N48O63 |
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容